MOUNTAIN VIEW, CA--(Marketwire - Apr 13, 2011) - Amunix, Inc. today announced that it has entered into an exclusive worldwide research collaboration and option agreement with Biogen Idec (NASDAQ: BIIB) to research and develop novel, fully-recombinant blood factors (Factors IX, VIII and VIIa) with improved therapeutic properties. The partnership will combine Amunix's protein half-life engineering expertise, based on its proprietary XTEN technology, and Biogen Idec's broad range of capabilities in research, manufacturing and clinical development of recombinant blood factors for hemophilia.
"Biogen Idec is pleased to initiate research on this innovative technology in collaboration with Amunix," said Glenn Pierce, Senior Vice President of